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Issociation of the 719Arg
ariant of KIF6 With Both
ncreased Risk of Coronary
vents and With Greater
esponse to Statin Therapy
e read with interest the editorial comment (1) accompanying 3
eports that described the association of the 719Arg allele of KIF6
ith both increased risk of coronary heart disease and with
esponse to statin treatment (2–4). However, we would like to
omment on 2 assertions made in that evaluation of the work. The
ditorial stated that KIF6 is not expressed in the vasculature. One
ould expect a gene with a biologically plausible role in coronary
eart disease to be expressed in coronary arteries, and, in fact, KIF6
s expressed in coronary arteries and other vascular tissue. A
triking example of KIF6 expression in human coronary arteries
an be seen in the data generated by King et al. (5). Their data
ndicated that, in some human coronaries, KIF6 is among the top
% of overexpressed genes, based on a study of over 20,000 genes
see GEO accession number GDS1597 at http://www.ncbi.
lm.nih.gov/projects/geo/) .
The editorial also stated that the KIF6 association studies were
estricted to analysis of only 1 single nucleotide polymorphism
SNP) in the KIF6 gene. In fact, Iakoubova et al. (2) reports an
nalysis of 26 additional SNPs in a 95.5-kb interval of Chr 6 that
urrounds the KIF6 Trp719Arg SNP. These 26 additional SNPs
ould also be considered surrogates (or tagging SNPs) for 117
dditional SNPs in this interval.
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eply
thank Dr. Iakoubova and colleagues for the information (1–4).
hey cite King et al. (5), who described detection of messenger
ibonucleic acid (mRNA) expression by microarray in coronary
egments isolated from explanted hearts of 22 patients, mostly
ith ischemic heart disease. The main findings were decreased
xpression levels of smooth muscle cell genes and increased levels
f immune/inflammatory markers. However, I did not find any
eference to KIF6 (5). The microarray data, which requires
alidation by another technique, is posted at NCBI-GEO at
ttp://www.ncbi.nlm.nih.gov/sites/entrez. It shows increased
RNA levels of KIF6 in some coronary segments but reduced or
nchanged levels in others. The data do not specify expression of
IF6 in normal coronaries, a prerequisite for establishing the
ausality, as the cause (expression) has to precede the effect. Dr.
akoubova and colleagues indicate that they analyzed 26 additional
ingle nucleotide polymorphisms (SNPs) at the KIF6 locus in 1 of
he 3 study populations. All were in linkage disequilibrium (LD)
ot only with the Trp719Arg but also with 117 additional SNPs.
n this scenario, Trp719Arg may not be the true susceptibility
NP or KIF6 the true risk gene. The LD structure of the region
hould be analyzed, preferably in all 3 study populations, to
dentify other putative candidates. Mechanistic studies are neces-
ary to distinguish the true susceptibility allele (gene) from those in
D with the risk allele (gene).
The most important impact of the findings, if proven to be true, would
e in implicating a new pathway for the pathogenesis of coronary
therosclerosis and, hence, novel therapeutic targets. Most susceptibility
lleles for complex traits, because of a small effect size on absolute risk, are
nlikely to portend meaningful impact on pre-clinical diagnosis, early risk
tratification, early intervention, prognostication, or individualization of
herapy. Dr. Iakoubova and colleagues have a tremendous opportunity
o rise to the challenge by delineating the molecular mechanism(s) by
hich Try719Arg in KIF6 predisposes to coronary atherosclerosis, its
linical complications, or response to statins. By doing so, they could
ake an endurable impact in the care of millions of people worldwide.
therwise, I humbly submit that the findings are unlikely to fulfill the
ate Dr. Koshland’s Cha-Cha-Cha theory of scientific discoveries (6).
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